Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.

ABSTRACT:

Background

Chronic granulomatous disease (CGD) is caused by defects in any 1 of the 6 subunits forming the nicotinamide adenine dinucleotide phosphate oxidase complex 2 (NOX2), leading to severely reduced or absent phagocyte-derived reactive oxygen species production. Almost 50% of patients with CGD have inflammatory bowel disease (CGD-IBD). While conventional IBD therapies can treat CGD-IBD, their benefits must be weighed against the risk of infection. Understanding the impact of NOX2 defects on the intestinal microbiota may lead to the identification of novel CGD-IBD treatments.

Objective

We sought to identify microbiome and metabolome signatures that can distinguish individuals with CGD and CGD-IBD.

Methods

We conducted a cross-sectional observational study of 79 p

SUBMITTER: Chandrasekaran P 

PROVIDER: S-EPMC11279821 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature